Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ROCK1 mRNA 3'-untranslated region (3'-UTR) is a critical regulatory segment of the messenger RNA encoding Rho-associated coiled-coil containing protein kinase 1. This region contains multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins that dictate the stability and translational efficiency of the ROCK1 transcript (Luo et al., 2011, PMID: 21602826). ROCK1 itself is a key downstream effector of the RhoA GTPase, playing a central role in actin cytoskeleton organization, cell adhesion, and motility (UniProt Q13464). Dysregulation of the ROCK1 mRNA 3'-UTR, often through the loss of inhibitory miRNA binding, leads to ROCK1 overexpression, which is a hallmark of metastatic progression in various cancers and contributes to cardiovascular and fibrotic diseases (Ueno et al., 2011, PMID: 21135154). Therapeutic strategies targeting this region involve the use of miRNA mimics or antisense oligonucleotides to suppress ROCK1 expression at the post-transcriptional level. These RNA-based approaches aim to reduce ROCK1 protein levels more selectively than traditional ATP-competitive kinase inhibitors, which often face challenges with isoform selectivity and systemic toxicity. Current research focuses on optimizing delivery systems to ensure these therapeutic agents reach target tissues effectively while minimizing off-target effects (Crooke et al., 2018, PMID: 29574378).
Post-transcriptional gene silencing via RNA interference (RNAi) or antisense-mediated mRNA degradation, leading to reduced ROCK1 protein synthesis.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho-associated coiled-coil containing protein kinase 1 messenger RNA 3' untranslated region (ROCK1 mRNA 3'-UTR).